RT Book, Section
A1 Dobesh, Paul P.
A2 DiPiro, Joseph T.
A2 Talbert, Robert L.
A2 Yee, Gary C.
A2 Matzke, Gary R.
A2 Wells, Barbara G.
A2 Posey, L. Michael
SR Print(0)
ID 1163570368
T1 Stable Ischemic Heart Disease
T2 Pharmacotherapy: A Pathophysiologic Approach, 10e
YR 2017
FD 2017
PB McGraw-Hill Education
PP New York, NY
SN 9781259587481
LK accesspharmacy.mhmedical.com/content.aspx?aid=1163570368
RD 2024/04/23
AB Content  UpdateMay  20,  2019Update  on  Aspirin  Use  in  Primary  Prevention  of  Cardiovascular  Disease:  The  American  College  of  Cardiology  and  American  Heart  Association  (ACC/AHA)  published  a  guideline  for  the  primary  prevention  of  cardiovascular  disease.  The  2019  Guideline  reinforces  the  importance  of  adopting  lifelong,  healthy  dietary  and  exercise  habits  for  everyone.  In  addition,  tobacco  cessation,  weight  loss,  and  pharmacologic  treatment  to  address  risk  factors  for  atherosclerotic  cardiovascular  disease  (ASCVD),  such  as  hypertension  and  dyslipidemia,  are  given  strong  (Class  I)  recommendations.  Aspirin  should  be  used  infrequently  for  primary  prevention  of  ASCVD  because  its  potential  benefits  are  often  offset  by  increased  bleeding  risk.  A  team-based  approach  to  addressing  factors  that  increase  ASCVD  risk  is  strongly  endorsed  (Class  1A  recommendation).